Morphic Holding, Inc. (MORF) News
Filter MORF News Items
MORF News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MORF News Highlights
- For MORF, its 30 day story count is now at 2.
- Over the past 19 days, the trend for MORF's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest MORF News From Around the Web
Below are the latest news stories about MORPHIC HOLDING INC that investors may wish to consider to help them evaluate MORF as an investment opportunity.
Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 92.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
We're Not Very Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 160.84%: Read This Before Placing a BetThe consensus price target hints at a 160.8% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Morphic to Present at November Investor ConferencesWALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Jefferies London Healthcare Conference Fireside Chat Date: Tuesday, November 14, 2023Time: 5:00 PM GMT/12:00 PM ETA live webcast of |
Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the UpgradeMorphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Morphic Holding Inc (MORF) Reports Q3 2023 Loss of $36.2 Million, Ends Quarter with $725. ...Company Continues to Show Positive Results in Phase 2a and 2b Trials of MORF-057 |
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new gen |
This Morphic Holding Insider Increased Their Holding By 16% Last YearLooking at Morphic Holding, Inc.'s ( NASDAQ:MORF ) insider transactions over the last year, we can see that insiders... |
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data SetWALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year an |